글로벌 폐/호흡기 약물 전달 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

폐/호흡기 약물 전달 시장 분석

폐/호흡기 약물 전달 시장은 천식 및 만성 폐쇄성 폐질환 (COPD) 과 같은 호흡기 질환의 증가 와 약물 전달 기술의 발전으로 인해 상당한 성장을 목격하고 있습니다. 최근 시장 혁신에는 디지털 기술을 활용하여 약물 복용 준수와 환자 결과를 개선하는 스마트 흡입기의 등장이 포함됩니다. 또한 기업들은 향상된 생체 이용률과 치료제의 표적 전달을 제공하는 분무기 및 건조 분말 흡입기를 포함한 새로운 제형 및 전달 시스템의 연구 개발에 투자하고 있습니다. 제약 회사와 기술 회사 간의 협업은 인공 지능을 통합하여 개인화된 치료 계획을 수립하는 파트너십을 통해 고급 폐 약물 전달 시스템의 개발을 더욱 가속화하고 있습니다. 신흥 경제에서 인지도가 높아지고 의료 지출이 증가함에 따라 폐/호흡기 약물 전달 시장은 상당한 성장을 이룰 준비가 되어 있으며 의료 분야 전반에 걸쳐 이해 관계자에게 수익성 있는 기회를 제공합니다.

폐/호흡기 약물 전달 시장 규모

글로벌 폐/호흡기 약물 전달 시장 규모는 2023년에 601억 3천만 달러로 평가되었으며, 2031년까지 995억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

폐/호흡기 약물 전달 시장 동향

“ 스마트 인헤일러 채택 증가”

폐/호흡기 약물 전달 시장은 천식 및 만성 폐쇄성 폐질환(COPD)과 같은 호흡기 질환의 유병률 증가에 따라 상당한 성장을 목격하고 있습니다. 시장에서 두드러진 추세는 약물 복용 준수와 환자 관리를 개선하기 위해 디지털 기술을 통합한 스마트 흡입기의 채택이 증가하고 있다는 것입니다. 예를 들어, Propeller Health와 같은 회사는 약물 사용을 추적하고 환자와 의료 서비스 제공자에게 실시간 피드백을 제공하여 호흡기 질환을 더 잘 관리하는 데 도움이 되는 센서가 장착된 흡입기를 개발했습니다. 이 혁신은 환자가 약물 섭취를 모니터링하고 임상의가 치료 효능을 평가하는 데 도움이 되어 환자에게 힘을 실어줍니다. 효과적인 호흡 요법에 대한 수요가 계속 증가함에 따라 약물 전달 시스템에 첨단 기술을 통합하는 것이 환자 결과를 개선하고 시기적절한 개입을 용이하게 하며 궁극적으로 폐 약물 전달 솔루션의 환경을 재편하는 데 중요한 역할을 할 것으로 예상됩니다.

보고 범위 및 폐/호흡기 약물 전달 시장 세분화

Pulmonary/Respiratory Drug Delivery Market Definition

Pulmonary/respiratory drug delivery refers to the administration of therapeutic agents directly into the lungs via inhalation. This method allows for the rapid absorption of drugs through the pulmonary epithelium, enabling immediate effects, particularly for respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung infections. Various delivery devices are utilized in this process, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and smart inhalers, which often incorporate technology for enhanced medication adherence and monitoring.

Pulmonary/Respiratory Drug Delivery Market Dynamics

Drivers

• Rising Prevalence of Respiratory Diseases

The rising prevalence of respiratory diseases is a critical factor driving the demand for effective pulmonary drug delivery systems. Chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD) are becoming increasingly common, affecting millions of individuals worldwide. According to the World Health Organization (WHO), more than 400 million people globally suffer from asthma, highlighting the urgent need for innovative treatment options that ensure effective disease management. In addition, the growing recognition of asthma and COPD as significant public health challenges has prompted healthcare providers and policymakers to prioritize the development and accessibility of advanced pulmonary drug delivery systems. Consequently, driving the market expansion.

• Increasing Rate of Air Pollution

The increasing rate of air pollution is a significant driver of the pulmonary/respiratory drug delivery market, as it leads to a heightened risk of lung infections such as bronchitis and pneumonia. Polluted air can cause breathing difficulties and contribute to various severe lung issues. According to the World Health Organization (WHO), environmental air pollution is estimated to be responsible for approximately 16% of lung cancer deaths, around 17% of fatalities from ischemic heart disease and stroke, 25% of COPD deaths, and about 26% of respiratory infection-related deaths. Such alarming data underscores the urgent need for effective treatment options, which enhances the demand for pulmonary drug delivery systems. As air quality continues to decline, the market for innovative inhalation drug delivery is expected to expand, driven by the need for more effective respiratory treatments.

Opportunities

• Rising Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is playing a pivotal role in enhancing access to pulmonary drug delivery systems, particularly in emerging markets. For instance, according to the World Health Organization (WHO), healthcare spending in low- and middle-income countries is expected to increase significantly, with an estimated growth from $400 billion in 2020 to over $1 trillion by 2025. Such influx of capital is being directed towards upgrading healthcare facilities, improving diagnostic capabilities, and expanding the availability of essential medications, including advanced inhalation therapies. As a result, the expansion of healthcare infrastructure improves patient outcomes and create market growth opportunities for pulmonary drug delivery systems.

• Increasing Regulatory Support

Regulatory support plays a crucial role in fostering innovation within the pulmonary drug delivery market by streamlining the approval process for new products. For instance, the U.S. Food and Drug Administration (FDA) has implemented various initiatives, such as the Breakthrough Devices Program, designed to expedite the development and review of medical devices that offer significant advantages over existing alternatives. In 2023, the FDA approved over many new pulmonary drug delivery devices, reflecting its commitment to facilitating faster access to innovative therapies. Such regulatory support encourages manufacturers to invest in research and development and fosters collaboration between regulatory bodies and industry stakeholders, ensuring that safe and effective pulmonary delivery systems reach patients more quickly. As regulatory frameworks continue to evolve, they will play an increasingly important role in creating opportunities in the market and advancing the availability of cutting-edge respiratory treatments.

Restraints/Challenges

• High Costs Associated with Research and Development

High costs associated with research and development (R&D) pose a significant challenge in the pulmonary drug delivery market, particularly for smaller companies and startups. Developing innovative pulmonary drug delivery systems requires substantial financial investment across various stages, including formulation development, preclinical studies, and extensive clinical trials to demonstrate safety and efficacy. Such financial barriers can hinder smaller firms from bringing their products to market, as they often lack the capital necessary to fund lengthy and expensive clinical trials. In addition, the competitive landscape, dominated by well-established pharmaceutical companies with ample resources, makes it increasingly difficult for new entrants to secure funding. Consequently, the high costs of R&D can limit innovation and reduce the availability of novel pulmonary drug delivery solutions that could greatly benefit patients.

• Limited Formulation Stability and Variabile Dosing Consistency

The pulmonary/respiratory drug delivery market faces significant challenges related to poor formulation stability for drugs and improper dosing reproducibility, which can adversely affect therapeutic outcomes. Many pulmonary formulations are sensitive to environmental factors such as humidity and temperature, leading to instability that compromises drug efficacy. In addition, improper dosing reproducibility remains a critical issue, as variability in inhaler techniques among patients can result in inconsistent delivery of medication. As a result, the challenges of poor formulation stability and improper dosing reproducibility significantly hinder the effectiveness of therapies in the pulmonary/respiratory drug delivery market, impacting patient outcomes and overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pulmonary/Respiratory Drug Delivery Market Scope

The market is segmented on the basis of product, canister type, application, distribution channel, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Formulation Type
  • Suspension Aerosol
  • Solution Aerosol
  • Dry Powder Formulation
• Device Type
  • Metred Dose Inhalers(MDI)
  • Dry Powder Inhalers(DPI)
  • Nebulizers

Canister Type

• Plain Canisters
• Coated Canisters

Application

• Chronic Obstructive Pulmonary Disease
• Asthma
• Cystic Fibrosis

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• E-Commerce

End User

• Hospitals
• Clinics
• Home Care Settings

Pulmonary/Respiratory Drug Delivery Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, canister type, application, distribution channel, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a dominant position in the pulmonary and respiratory drug delivery market, primarily due to the presence of significant key players and the rising demand for advanced diagnostic devices such as pulmonary drug delivery systems (PDDS). The region also benefits from an increase in disposable income, which allows for greater investment in healthcare technologies. Furthermore, the surging incidence of various respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), is driving the need for effective drug delivery solutions, further solidifying North America's market leadership in this sector.

Asia-Pacific region is anticipated to experience substantial growth in the pulmonary and respiratory drug delivery market from 2024 to 2031, driven by the rising prevalence of asthma and allergic rhinitis among patients. In addition, an uptick in research and development activities in the region is fostering innovation and the introduction of new therapeutic options. Furthermore, heightened awareness campaigns initiated by public and private organizations are playing a crucial role in educating the population about respiratory health, thereby increasing demand for effective treatment solutions and contributing to the market's expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Pulmonary/Respiratory Drug Delivery Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 폐/호흡기 약물 전달 시장 리더는 다음과 같습니다.

• GSK plc (영국)
• 베링거인겔하임인터내셔널(독일)
• 3M(미국)
• 아스트라제네카(영국)
• 머크앤코(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Thermo Fisher Scientific Inc. (미국)
• 브루커(미국)
• 애벗(미국)
• 노바티스 AG(스위스)
• 클라크 인터내셔널(영국)
• Koninklijke Philips NV(네덜란드)
• OMRON 주식회사(일본)
• 브릭스 헬스케어(영국)
• 스미토모파마아메리카 주식회사(US)

폐/호흡기 약물 전달 시장의 최신 개발

• 2024년 4월, Launch Therapeutics, Inc.와 Teva Pharmaceutical Industries Ltd.는 Teva의 ICS-SABA(TEV-248)에 대한 임상 연구 프로그램을 가속화하기 위한 임상 협력 계약을 발표했습니다. 이 파트너십은 두 회사의 전문성을 활용하여 흡입 코르티코스테로이드와 단기 작용 베타 작용제를 결합하여 호흡기 질환 관리를 개선하는 이 혁신적인 치료법의 개발을 강화하도록 설계되었습니다.
• 2024년 4월, Nebu-Flow는 전 세계적으로 사망과 장애의 주요 원인인 호흡기 질환 환자를 위한 차세대 흡입 약물 개발을 촉진하기 위해 628만 달러의 추가 투자를 성공적으로 확보했습니다. 이 회사의 네뷸라이저 플랫폼은 현재 기술에 비해 여러 가지 이점을 제공하도록 설계되었습니다.

SKU-25290